Evidence map›Paper›PMID 41024871›Full record

ArticleWorld journal of hepatology2025

Albumin-bilirubin score reflects the extent of liver fibrosis in chronic hepatitis C patients treated with direct-acting antivirals.

Mohammed Ewid, Hossam Sherif, Nazmus Saquib, Ammar Mohammed Alammari, Amro Abdelaziz Mohammed Ismail, Mohammed H Alkahlot, Ziyad T Ahmed, Faisal Zain Mohammed Al-Zabidi, Nawaf Al Mutiri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammed EwidDepartment of Internal Medicine, College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah 51941, Qassim, Saudi Arabia.
Hossam SherifDepartment of Critical Care Medicine, College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah 51941, Qassim, Saudi Arabia.
Nazmus SaquibDepartment of Epidemiology, College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah 51941, Qassim, Saudi Arabia.
Ammar Mohammed AlammariDepartment of Gastroenterology, King Fahad Specialist Hospital, Buraydah 52366, Qassim, Saudi Arabia.
Amro Abdelaziz Mohammed IsmailDepartment of Internal Medicine, Faculty of Medicine, Cairo University, Cairo 11562, Egypt.
Mohammed H AlkahlotCollege of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah 51941, Qassim, Saudi Arabia.
Ziyad T AhmedCollege of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah 51941, Qassim, Saudi Arabia.
Faisal Zain Mohammed Al-ZabidiCollege of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah 51941, Qassim, Saudi Arabia.
Nawaf Al MutiriDepartment of Gastroenterology, King Fahad Specialist Hospital, Buraydah 52366, Qassim, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe albumin-bilirubin (ALBI) score was developed as a prognostic tool for patients with hepatocellular carcinoma. However, its new role as an indicator of liver fibrosis in chronic hepatitis C virus (HCV) patients is under investigation.

aimTo investigate the ALBI score as a non-invasive means of assessing the extent of liver fibrosis in chronic HCV patients.

methodsWe evaluated hospital records of 231 eligible chronic HCV patients from King Fahad Specialist Hospital in Buraydah, Saudi Arabia. Demographic/clinical data, liver function tests, non-invasive tests for liver fibrosis, and ALBI score/grades were evaluated before and two years after direct-acting antivirals (DAA) treatment.

resultsThe median ALBI score improved from -2.51 to -2.62 after DAA treatment (

conclusionThe ALBI score appears to be a useful non-invasive marker for assessing liver fibrosis in chronic HCV patients and may serve as a valuable tool for monitoring hepatic function during and after DAA treatment.

Indexed as

Albumin-bilirubin scoreChronic hepatitis CDirect-acting antiviral agentsLiver fibrosisLiver function

Identifiers

PMID41024871
PMCPMC12476727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.